Valion Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $757.6K
- Price
- $0.1825
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.25%
- Volume
- 27.4M
About
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Quick stats
Shares outstanding4.2M
Computed float4.0M
Float / shares96.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001787740
Websitehttps://valionbio.com
AI Summary
AI-generated1/19
standardbullishregulatory
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
Ukraine's Ministry of Health accepted the Entolimod dossier for formal review on July 22, 2026, initiating the technical assessment phase under the Regulatory Equivalence Pathway.
Valion Bio believes a regulatory decision could occur as early as the fourth quarter of 2026, which would mark Entolimod's first national registration and open a pathway to potential government stockpiling.
Management emphasized that while registration is a critical milestone, no procurement or stockpiling agreement has been executed and registration alone would not generate revenue.
Red flags
- No procurement, purchase, or stockpiling agreement has been executed
- Registration alone would not result in revenue
- Geopolitical developments in Ukraine could disrupt or terminate the regulatory process